Focal launches FocalSeal through Ethicon:
This article was originally published in Clinica
Focal is to launch its FocalSeal surgical sealant in New Zealand, Australia, Hong Kong and South Africa, through Johnson & Johnson subsidiary Ethicon. Lexington, Massachusetts-based Focal's product will be marketed and distributed under the brandname Advaseal. The product is a synthetic, absorbable liquid sealant which is designed to prevent air leaks during lung surgery. Visible light from a specially-designed light source transforms the liquid into a tissue-adherent gel which creates a leak-proof seal over the wound.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.